Establishment through persistent technical refinement and industrial-scale manufacturing capability, providing reliable chemical foundations for global markets.
Hebei Kanghua Pharmaceutical Factory (the predecessor of the company) was established.
Hebei Dacheng Pharmaceutical Factory (the predecessor of the company) was established.
CNNC Jinyuan Uranium Co., Ltd. acquired Kanghua Pharmaceutical Factory and Dacheng Pharmaceutical Factory, and renamed them Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. and Hebei Shengxue Kanghua Pharmaceutical Co., Ltd.
Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. and Hebei Shengxue Kanghua Pharmaceutical Co., Ltd. merged to form Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. CNNC Jinyuan Uranium Co., Ltd. held 84.23% of the shares, and the employee stock ownership association held 15.77%.
The company acquired Tangshan Huaqing Biochemical Pharmaceutical Co., Ltd. and established a wholly-owned subsidiary — Hebei Shengxue Dacheng Tangshan Pharmaceutical Co., Ltd.
Zhejiang Shenghua Biok Biology Co., Ltd. completes a capital increase in Shengxue Dacheng, becoming its second-largest shareholder. Post-transaction, CNNC Jinyuan Uranium holds 51% equity, and Shenghua Biok holds 49%.
Inner Mongolia Shengxue Dacheng Pharmaceutical Co., Ltd. was established, marking the official launch of the high-end pharmaceutical base project in Kailu County, Inner Mongolia Autonomous Region.
The first batch of products at Inner Mongolia Shengxue Dacheng Pharmaceutical Co., Ltd. passed the trial production successfully.
We continue to optimize our manufacturing framework, integrating high-purity synthesis expertise with sustainable production protocols to drive global chemical supply excellence.
Partner With Us
